Recursion Pharmaceuticals (RXRX) Goldman Sachs 45th Annual Global Healthcare Conference summary

Platform overview and technology differentiation

• Operating system integrates automated wet lab, computational dry lab, and advanced software for large-scale biological and chemical data generation and analysis.

• Over 250 million experiments conducted, with up to 2 million per week, supporting mapping and validation of biological, chemical, and patient-centric insights.

• Platform enables iterative optimization between in silico and physical experiments, supporting translation from discovery to IND-enabling studies.

• Differentiation in TechBio space centers on scale of proprietary data, compute, and impact, with continuous integration and automation of new technologies.

• Proprietary data scaled to over 50 PB, with 1 million transcriptomes sequenced and partnerships for multimodal patient-centric data.

Clinical pipeline and milestones

• Seven clinical readouts expected in 18 months: five phase II and two phase I, spanning rare diseases and oncology.

• Upcoming phase II readouts include cerebral cavernous malformation (Q3), neurofibromatosis type 2 (Q4), familial adenomatous polyposis, and AXIN1 APC-driven mutant cancers (first half next year).

• Phase II trial in C. difficile infection to initiate this year; phase I trials in HR-proficient cancer and fibrotic disease progressing toward IND submission.

• Clinical measures focus on safety, tolerability, progression-free survival, response rates, and disease-specific endpoints such as polyp burden and lesion changes.

• Earlier programs leveraged phenotypic identification and known chemical entities, while newer programs integrate novel chemistry and patient-centric data.

Mechanistic rationale and trial design

• Cerebral cavernous malformation program targets regulation of FoxO1 and superoxide dismutase 2 to maintain endothelial health; preclinical and phase I data show safety and lesion impact.

• Disease complexity and lack of awareness have limited prior clinical trials; current approach uses alternative mechanisms and objective/subjective efficacy measures.

• Phase II trial is first industry-sponsored in this indication, with endpoints including MRI lesion metrics and patient-reported outcomes.

• Movement in any efficacy variable may warrant program advancement, with FDA collaboration on defining clinical meaningfulness.